Amphastar Pharmaceuticals Inc Expected to Post Q1 2020 Earnings of $0.16 Per Share (AMPH)

Share on StockTwits

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) – Piper Jaffray Companies issued their Q1 2020 EPS estimates for Amphastar Pharmaceuticals in a research report issued on Tuesday, March 12th. Piper Jaffray Companies analyst D. Amsellem anticipates that the company will earn $0.16 per share for the quarter. Piper Jaffray Companies has a “Neutral” rating and a $23.00 price target on the stock. Piper Jaffray Companies also issued estimates for Amphastar Pharmaceuticals’ Q2 2020 earnings at $0.23 EPS, Q3 2020 earnings at $0.28 EPS and Q4 2020 earnings at $0.30 EPS.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $89.69 million during the quarter, compared to analysts’ expectations of $75.46 million. Amphastar Pharmaceuticals had a positive return on equity of 3.25% and a negative net margin of 1.96%.

A number of other analysts have also recently issued reports on AMPH. BidaskClub cut Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. Finally, Needham & Company LLC cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 target price for the company. in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $23.73.

Shares of NASDAQ AMPH opened at $20.23 on Friday. The stock has a market capitalization of $1.11 billion, a P/E ratio of 96.33, a PEG ratio of 1.81 and a beta of 1.40. The company has a quick ratio of 1.34, a current ratio of 2.02 and a debt-to-equity ratio of 0.10. Amphastar Pharmaceuticals has a 52-week low of $14.40 and a 52-week high of $25.43.

A number of institutional investors and hedge funds have recently bought and sold shares of AMPH. Wells Fargo & Company MN raised its stake in Amphastar Pharmaceuticals by 22.2% during the 3rd quarter. Wells Fargo & Company MN now owns 241,037 shares of the company’s stock valued at $4,638,000 after acquiring an additional 43,727 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Amphastar Pharmaceuticals by 6.4% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 152,300 shares of the company’s stock valued at $2,930,000 after acquiring an additional 9,200 shares during the last quarter. Bessemer Group Inc. purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $620,000. Bank of New York Mellon Corp raised its stake in Amphastar Pharmaceuticals by 2.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 418,903 shares of the company’s stock valued at $8,060,000 after acquiring an additional 10,837 shares during the last quarter. Finally, Martingale Asset Management L P purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $2,033,000. 48.22% of the stock is owned by hedge funds and other institutional investors.

In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 15,497 shares of the company’s stock in a transaction that occurred on Wednesday, January 23rd. The stock was sold at an average price of $22.39, for a total transaction of $346,977.83. Following the completion of the sale, the insider now directly owns 168,518 shares of the company’s stock, valued at approximately $3,773,118.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 3,245 shares of the company’s stock in a transaction that occurred on Wednesday, January 2nd. The shares were sold at an average price of $19.52, for a total value of $63,342.40. Following the sale, the chief financial officer now directly owns 75,550 shares of the company’s stock, valued at $1,474,736. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 87,222 shares of company stock valued at $2,037,797. 31.50% of the stock is owned by company insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

LPL Financial  Cut to Hold at BidaskClub
LPL Financial Cut to Hold at BidaskClub
KEYW  Rating Increased to Buy at BidaskClub
KEYW Rating Increased to Buy at BidaskClub
IAC/InterActiveCorp  Raised to Buy at BidaskClub
IAC/InterActiveCorp Raised to Buy at BidaskClub
Reviewing Guardant Health  & Its Competitors
Reviewing Guardant Health & Its Competitors
Head to Head Comparison: Red Lion Hotels  & Its Rivals
Head to Head Comparison: Red Lion Hotels & Its Rivals
$480.90 Million in Sales Expected for Kraton Corp  This Quarter
$480.90 Million in Sales Expected for Kraton Corp This Quarter


© 2006-2019 Ticker Report